Revealing the complexity of breast cancer by next generation sequencing

Cancers

Volumn 7, Issue 4, 2015, Pages 2183-2200

  Verigos, John ^a,b   Magklara, Angeliki ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b INSTITUTE OF COMPUTER SCIENCE   (Greece)

Author keywords

Breast cancer; Driver genes; Gene fusions; Intratumor heterogeneity; Next generation sequencing; Targeted therapy

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICRORNA; PERTUZUMAB; PROGESTERONE RECEPTOR; TRASTUZUMAB;

BREAST CANCER; BREAST CANCER CELL LINE; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; DNA METHYLATION; DRUG TARGETING; GENE FUSION; GENE MUTATION; GENOMICS; HUMAN; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; NEXT GENERATION SEQUENCING; REVIEW; RNA SEQUENCE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GENE;

EID: 84946825685     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7040885     Document Type: Review

References (94)

1. Nakagawa, H.; Wardell, C.P.; Furuta, M.; Taniguchi, H.; Fujimoto, A. Cancer whole-genome sequencing: Present and future. Oncogene 2015. [CrossRef] [PubMed]
2. Feng, H.; Qin, Z.; Zhang, X. Opportunities and methods for studying alternative splicing in cancer with rna-seq. Cancer Lett. 2013, 340, 179-191. [CrossRef] [PubMed]
3. Stirzaker, C.; Taberlay, P.C.; Statham, A.L.; Clark, S.J. Mining cancer methylomes: Prospects and challenges. Trends Genet. 2013, 30, 75-84. [CrossRef] [PubMed]
4. Ding, L.; Wendl, M.C.; McMichael, J.F.; Raphael, B.J. Expanding the computational toolbox for mining cancer genomes. Nat. Rev. Genet. 2014, 15, 556-570. [CrossRef] [PubMed]
5. Torkamani, A.; Schork, N.J. Prediction of cancer driver mutations in protein kinases. Cancer Res. 2008, 68, 1675-1682. [CrossRef] [PubMed]
6. Stratton, M.R.; Campbell, P.J.; Futreal, P.A. The cancer genome. Nature 2009, 458, 719-724. [CrossRef] [PubMed]
7. Stephens, P.J.; Tarpey, P.S.; Davies, H.; Van Loo, P.; Greenman, C.; Wedge, D.C.; Nik-Zainal, S.; Martin, S.; Varela, I.; Bignell, G.R.; et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486, 400-404. [CrossRef] [PubMed]
8. Banerji, S.; Cibulskis, K.; Rangel-Escareno, C.; Brown, K.K.; Carter, S.L.; Frederick, A.M.; Lawrence, M.S.; Sivachenko, A.Y.; Sougnez, C.; Zou, L.; et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486, 405-409. [CrossRef] [PubMed]
9. Shah, S.P.; Roth, A.; Goya, R.; Oloumi, A.; Ha, G.; Zhao, Y.; Turashvili, G.; Ding, J.; Tse, K.; Haffari, G.; et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486, 395-399. [CrossRef] [PubMed]
10. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61-70.
11. Forbes, S.A.; Bhamra, G.; Bamford, S.; Dawson, E.; Kok, C.; Clements, J.; Menzies, A.; Teague, J.W.; Futreal, P.A.; Stratton, M.R. The catalogue of somatic mutations in cancer (cosmic). Curr. Protoc. Hum. Genet. 2008, 57. [CrossRef]
12. Carbone, M.; Yang, H.; Pass, H.I.; Krausz, T.; Testa, J.R.; Gaudino, G. Bap1 and cancer. Nat. Rev. Cancer 2013, 13, 153-159. [CrossRef] [PubMed]
13. Manceau, G.; Letouze, E.; Guichard, C.; Didelot, A.; Cazes, A.; Corte, H.; Fabre, E.; Pallier, K.; Imbeaud, S.; le Pimpec-Barthes, F.; et al. Recurrent inactivating mutations of arid2 in non-small cell lung carcinoma. Int. J. Cancer 2013, 132, 2217-2221. [CrossRef] [PubMed]
14. Zhao, H.; Wang, J.; Han, Y.; Huang, Z.; Ying, J.; Bi, X.; Zhao, J.; Fang, Y.; Zhou, H.; Zhou, J.; et al. Arid2: A new tumor suppressor gene in hepatocellular carcinoma. Oncotarget 2011, 2, 886-891. [CrossRef] [PubMed]
15. Abdel-Wahab, O.; Adli, M.; LaFave, L.M.; Gao, J.; Hricik, T.; Shih, A.H.; Pandey, S.; Patel, J.P.; Chung, Y.R.; Koche, R.; et al. Asxl1 mutations promote myeloid transformation through loss of prc2-mediated gene repression. Cancer Cell 2012, 22, 180-193. [CrossRef] [PubMed]
16. Gelsi-Boyer, V.; Brecqueville, M.; Devillier, R.; Murati, A.; Mozziconacci, M.J.; Birnbaum, D. Mutations in asxl1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J. Hematol. Oncol. 2012, 5, 12. [CrossRef] [PubMed]
17. Metzeler, K.H.; Becker, H.; Maharry, K.; Radmacher, M.D.; Kohlschmidt, J.; Mrozek, K.; Nicolet, D.; Whitman, S.P.; Wu, Y.Z.; Schwind, S.; et al. Asxl1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal aml within the eln favorable genetic category. Blood 2011, 118, 6920-6929. [CrossRef] [PubMed]
18. Wu, J.N.; Roberts, C.W. Arid1a mutations in cancer: Another epigenetic tumor suppressor? Cancer Discov. 2013, 3, 35-43. [CrossRef] [PubMed]
19. Markowitz, S.D.; Bertagnolli, M.M. Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 2009, 361, 2449-2460. [CrossRef] [PubMed]
20. Yin, S.; Yang, J.; Lin, B.; Deng, W.; Zhang, Y.; Yi, X.; Shi, Y.; Tao, Y.; Cai, J.; Wu, C.I.; et al. Exome sequencing identifies frequent mutation of mll2 in non-small cell lung carcinoma from chinese patients. Sci. Rep. 2014, 4, 6036. [CrossRef] [PubMed]
21. Natarajan, T.G.; Kallakury, B.V.; Sheehan, C.E.; Bartlett, M.B.; Ganesan, N.; Preet, A.; Ross, J.S.; Fitzgerald, K.T. Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon. Cancer Cell Int. 2010, 10, 13. [CrossRef] [PubMed]
22. Martin, P.; Leighl, N.B.; Tsao, M.S.; Shepherd, F.A. Kras mutations as prognostic and predictive markers in non-small cell lung cancer. J. Thorac. Oncol. 2013, 8, 530-542. [CrossRef] [PubMed]
23. Davis, S.J.; Choong, D.Y.; Ramakrishna, M.; Ryland, G.L.; Campbell, I.G.; Gorringe, K.L. Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer. BMC Cancer 2011, 11, 173. [CrossRef] [PubMed]
24. Davies, C.; Tournier, C. Exploring the function of the jnk (c-jun n-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies. Biochem. Soc. Trans. 2012, 40, 85-89. [CrossRef] [PubMed]
25. Angel, P.; Hattori, K.; Smeal, T.; Karin, M. The jun proto-oncogene is positively autoregulated by its product, jun/ap-1. Cell 1988, 55, 875-885. [CrossRef]
26. Park, H.S.; Kim, M.S.; Huh, S.H.; Park, J.; Chung, J.; Kang, S.S.; Choi, E.J. Akt (protein kinase b) negatively regulates SEK1 by means of protein phosphorylation. J. Biol. Chem. 2002, 277, 2573-2578. [CrossRef] [PubMed]
27. Zardavas, D.; Irrthum, A.; Swanton, C.; Piccart, M. Clinical management of breast cancer heterogeneity. Nat. Rev. Clin. Oncol. 2015, 12, 381-394. [CrossRef] [PubMed]
28. Perou, C.M.; Sorlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; et al. Molecular portraits of human breast tumours. Nature 2000, 406, 747-752. [CrossRef] [PubMed]
29. Eroles, P.; Bosch, A.; Perez-Fidalgo, J.A.; Lluch, A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat. Rev. 2012, 38, 698-707. [CrossRef] [PubMed]
30. Speck, N.A. Core binding factor and its role in normal hematopoietic development. Curr. Opin. Hematol. 2001, 8, 192-196. [CrossRef] [PubMed]
31. Yoshida, C.A.; Furuichi, T.; Fujita, T.; Fukuyama, R.; Kanatani, N.; Kobayashi, S.; Satake, M.; Takada, K.; Komori, T. Core-binding factor beta interacts with Runx2 and is required for skeletal development. Nat. Genet. 2002, 32, 633-638. [CrossRef] [PubMed]
32. Stender, J.D.; Kim, K.; Charn, T.H.; Komm, B.; Chang, K.C.; Kraus, W.L.; Benner, C.; Glass, C.K.; Katzenellenbogen, B.S. Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol. Cell. Biol. 2010, 30, 3943-3955. [CrossRef] [PubMed]
33. Chimge, N.O.; Frenkel, B. The runx family in breast cancer: Relationships with estrogen signaling. Oncogene 2012, 32, 2121-2130. [CrossRef] [PubMed]
34. Duployez, N.; Willekens, C.; Marceau-Renaut, A.; Boudry-Labis, E.; Preudhomme, C. Prognosis and monitoring of core-binding factor acute myeloid leukemia: Current and emerging factors. Expert Rev. Hematol. 2015, 8, 43-56. [CrossRef] [PubMed]
35. Davis, N.M.; Sokolosky, M.; Stadelman, K.; Abrams, S.L.; Libra, M.; Candido, S.; Nicoletti, F.; Polesel, J.; Maestro, R.; D'Assoro, A.; et al. Deregulation of the egfr/pi3k/pten/akt/mtorc1 pathway in breast cancer: Possibilities for therapeutic intervention. Oncotarget 2014, 5, 4603-4650. [CrossRef] [PubMed]
36. Foulkes, W.D.; Smith, I.E.; Reis-Filho, J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363, 1938-1948. [CrossRef] [PubMed]
37. Roychowdhury, S.; Chinnaiyan, A.M. Translating genomics for precision cancer medicine. Annu. Rev. Genom. Hum. Genet. 2014, 15, 395-415.
38. Yates, L.R.; Campbell, P.J. Evolution of the cancer genome. Nat. Rev. Genet. 2012, 13, 795-806. [CrossRef] [PubMed]
39. Ding, L.; Ellis, M.J.; Li, S.; Larson, D.E.; Chen, K.; Wallis, J.W.; Harris, C.C.; McLellan, M.D.; Fulton, R.S.; Fulton, L.L.; et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464, 999-1005. [CrossRef] [PubMed]
40. Shah, S.P.; Morin, R.D.; Khattra, J.; Prentice, L.; Pugh, T.; Burleigh, A.; Delaney, A.; Gelmon, K.; Guliany, R.; Senz, J.; et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461, 809-813. [CrossRef] [PubMed]
41. McCart Reed, A.E.; Kutasovic, J.R.; Lakhani, S.R.; Simpson, P.T. Invasive lobular carcinoma of the breast: Morphology, biomarkers and omics. Breast Cancer Res. 2015, 17, 12. [CrossRef] [PubMed]
42. Rakha, E.A.; Reis-Filho, J.S.; Ellis, I.O. Basal-like breast cancer: A critical review. J. Clin. Oncol. 2008, 26, 2568-2581. [CrossRef] [PubMed]
43. Mao, J.H.; Kim, I.J.; Wu, D.; Climent, J.; Kang, H.C.; DelRosario, R.; Balmain, A. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008, 321, 1499-1502. [CrossRef] [PubMed]
44. Zhang, W.; Koepp, D.M. Fbw7 isoform interaction contributes to cyclin e proteolysis. Mol. Cancer Res. 2006, 4, 935-943. [CrossRef] [PubMed]
45. Welcker, M.; Clurman, B.E. FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 2008, 8, 83-93. [CrossRef] [PubMed]
46. Bajpai, S.; Feng, Y.; Krishnamurthy, R.; Longmore, G.D.; Wirtz, D. Loss of alpha-catenin decreases the strength of single e-cadherin bonds between human cancer cells. J. Biol. Chem. 2009, 284, 18252-18259. [CrossRef] [PubMed]
47. Plumb, C.L.; Adamcic, U.; Shahrzad, S.; Minhas, K.; Adham, S.A.; Coomber, B.L. Modulation of the tumor suppressor protein alpha-catenin by ischemic microenvironment. Am. J. Pathol. 2009, 175, 1662-1674. [CrossRef] [PubMed]
48. Wang, Y.; Navin, N.E. Advances and applications of single-cell sequencing technologies. Mol. Cell 2015, 58, 598-609. [CrossRef] [PubMed]
49. Navin, N.; Kendall, J.; Troge, J.; Andrews, P.; Rodgers, L.; McIndoo, J.; Cook, K.; Stepansky, A.; Levy, D.; Esposito, D.; et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472, 90-94. [CrossRef] [PubMed]
50. Wang, Y.;Waters, J.; Leung, M.L.; Unruh, A.; Roh, W.; Shi, X.; Chen, K.; Scheet, P.; Vattathil, S.; Liang, H.; et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014, 512, 155-160. [CrossRef] [PubMed]
51. Nik-Zainal, S.; Alexandrov, L.B.; Wedge, D.C.; van Loo, P.; Greenman, C.D.; Raine, K.; Jones, D.; Hinton, J.; Marshall, J.; Stebbings, L.A.; et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149, 979-993. [CrossRef] [PubMed]
52. Conticello, S.G. The aid/apobec family of nucleic acid mutators. Genome Biol. 2008, 9, 229. [CrossRef] [PubMed]
53. Alexandrov, L.B.; Nik-Zainal, S.; Wedge, D.C.; Aparicio, S.A.; Behjati, S.; Biankin, A.V.; Bignell, G.R.; Bolli, N.; Borg, A.; Borresen-Dale, A.L.; et al. Signatures of mutational processes in human cancer. Nature 2013, 500, 415-421. [CrossRef] [PubMed]
54. Swanton, C.; McGranahan, N.; Starrett, G.J.; Harris, R.S. Apobec enzymes: Mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 2015, 5, 704-712. [CrossRef] [PubMed]
55. Wright, R.L.; Vaughan, A.T. A systematic description of mll fusion gene formation. Crit. Rev. Oncol. Hematol. 2014, 91, 283-291. [CrossRef] [PubMed]
56. Robinson, D.R.; Kalyana-Sundaram, S.; Wu, Y.M.; Shankar, S.; Cao, X.; Ateeq, B.; Asangani, I.A.; Iyer, M.; Maher, C.A.; Grasso, C.S.; et al. Functionally recurrent rearrangements of the mast kinase and notch gene families in breast cancer. Nat. Med. 2011, 17, 1646-1651. [CrossRef] [PubMed]
57. Edgren, H.; Murumagi, A.; Kangaspeska, S.; Nicorici, D.; Hongisto, V.; Kleivi, K.; Rye, I.H.; Nyberg, S.; Wolf, M.; Borresen-Dale, A.L.; et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol. 2011, 12, R6. [CrossRef] [PubMed]
58. Kalyana-Sundaram, S.; Shankar, S.; Deroo, S.; Iyer, M.K.; Palanisamy, N.; Chinnaiyan, A.M.; Kumar-Sinha, C. Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. Neoplasia 2012, 14, 702-708. [CrossRef] [PubMed]
59. Varley, K.E.; Gertz, J.; Roberts, B.S.; Davis, N.S.; Bowling, K.M.; Kirby, M.K.; Nesmith, A.S.; Oliver, P.G.; Grizzle, W.E.; Forero, A.; et al. Recurrent read-through fusion transcripts in breast cancer. Breast Cancer Res. Treat. 2014, 146, 287-297. [CrossRef] [PubMed]
60. Zhou, J.; Liao, J.; Zheng, X.; Shen, H. Chimeric RNAs as potential biomarkers for tumor diagnosis. BMB Rep. 2012, 45, 133-140. [CrossRef] [PubMed]
61. Bartel, D.P. Micrornas: Target recognition and regulatory functions. Cell 2009, 136, 215-233. [CrossRef] [PubMed]
62. Hayes, J.; Peruzzi, P.P.; Lawler, S. MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol. Med. 2013, 20, 460-469. [CrossRef] [PubMed]
63. Graveel, C.R.; Calderone, H.M.; Westerhuis, J.J.; Winn, M.E.; Sempere, L.F. Critical analysis of the potential for microrna biomarkers in breast cancer management. Breast Cancer (Dove. Med. Press) 2015, 7, 59-79. [PubMed]
64. Persson, H.; Kvist, A.; Rego, N.; Staaf, J.; Vallon-Christersson, J.; Luts, L.; Loman, N.; Jonsson, G.; Naya, H.; Hoglund, M.; et al. Identification of new micrornas in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res. 2011, 71, 78-86. [CrossRef] [PubMed]
65. Farazi, T.A.; Horlings, H.M.; Ten Hoeve, J.J.; Mihailovic, A.; Halfwerk, H.; Morozov, P.; Brown, M.; Hafner, M.; Reyal, F.; van Kouwenhove, M.; et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 2011, 71, 4443-4453. [CrossRef] [PubMed]
66. Pan, X.; Wang, Z.X.; Wang, R. MicroRNA-21: A novel therapeutic target in human cancer. Cancer Biol. Ther. 2010, 10, 1224-1232. [CrossRef] [PubMed]
67. Chang, Y.Y.; Kuo, W.H.; Hung, J.H.; Lee, C.Y.; Lee, Y.H.; Chang, Y.C.; Lin, W.C.; Shen, C.Y.; Huang, C.S.; Hsieh, F.J.; et al. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing. Mol. Cancer 2015, 14, 36. [CrossRef] [PubMed]
68. Volinia, S.; Croce, C.M. Prognostic microrna/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc. Natl. Acad. Sci. USA 2013, 110, 7413-7417. [CrossRef] [PubMed]
69. Sandoval, J.; Esteller, M. Cancer epigenomics: Beyond genomics. Curr. Opin. Genet. Dev. 2012, 22, 50-55. [CrossRef] [PubMed]
70. Mikeska, T.; Bock, C.; Do, H.; Dobrovic, A. DNA methylation biomarkers in cancer: Progress towards clinical implementation. Expert Rev. Mol. Diagn. 2012, 12, 473-487. [CrossRef] [PubMed]
71. Shull, A.Y.; Noonepalle, S.K.; Lee, E.J.; Choi, J.H.; Shi, H. Sequencing the cancer methylome. Methods Mol. Biol. 2014, 1238, 627-651.
72. Ruike, Y.; Imanaka, Y.; Sato, F.; Shimizu, K.; Tsujimoto, G. Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genom. 2010, 11, 137. [CrossRef] [PubMed]
73. Sun, Z.; Asmann, Y.W.; Kalari, K.R.; Bot, B.; Eckel-Passow, J.E.; Baker, T.R.; Carr, J.M.; Khrebtukova, I.; Luo, S.; Zhang, L.; et al. Integrated analysis of gene expression, cpg island methylation, and gene copy number in breast cancer cells by deep sequencing. PLoS ONE 2011, 6, e17490. [CrossRef] [PubMed]
74. Choi, Y.L.; Bocanegra, M.; Kwon, M.J.; Shin, Y.K.; Nam, S.J.; Yang, J.H.; Kao, J.; Godwin, A.K.; Pollack, J.R. Lyn is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res. 2010, 70, 2296-2306. [CrossRef] [PubMed]
75. Locke, W.J.; Zotenko, E.; Stirzaker, C.; Robinson, M.D.; Hinshelwood, R.A.; Stone, A.; Reddel, R.R.; Huschtscha, L.I.; Clark, S.J. Coordinated epigenetic remodelling of transcriptional networks occurs during early breast carcinogenesis. Clin. Epigenetics 2015, 7, 52. [CrossRef] [PubMed]
76. Jadhav, R.R.; Ye, Z.; Huang, R.L.; Liu, J.; Hsu, P.Y.; Huang, Y.W.; Rangel, L.B.; Lai, H.C.; Roa, J.C.; Kirma, N.B.; et al. Genome-wide DNA methylation analysis reveals estrogen-mediated epigenetic repression of metallothionein-1 gene cluster in breast cancer. Clin. Epigenetics 2015, 7, 13. [CrossRef] [PubMed]
77. Li, Z.; Guo, X.; Wu, Y.; Li, S.; Yan, J.; Peng, L.; Xiao, Z.; Wang, S.; Deng, Z.; Dai, L.; et al. Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients. Breast Cancer Res. Treat. 2015, 149, 767-779. [CrossRef] [PubMed]
78. Stirzaker, C.; Zotenko, E.; Song, J.Z.; Qu, W.; Nair, S.S.; Locke, W.J.; Stone, A.; Armstong, N.J.; Robinson, M.D.; Dobrovic, A.; et al. Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. Nat. Commun. 2015, 6, 5899. [CrossRef] [PubMed]
79. Carmona, F.J.; Esteller, M. DNA methylation in early neoplasia. Cancer Biomark 2010, 9, 101-111. [PubMed]
80. Ma, C.X.; Ellis, M.J. The cancer genome atlas: Clinical applications for breast cancer. Oncology (Williston Park) 2013, 27, 1263-1269, 1274-1279. [PubMed]
81. Ellis, M.J.; Ding, L.; Shen, D.; Luo, J.; Suman, V.J.; Wallis, J.W.; Van Tine, B.A.; Hoog, J.; Goiffon, R.J.; Goldstein, T.C.; et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012, 486, 353-360. [CrossRef] [PubMed]
82. Palmieri, C.; Patten, D.K.; Januszewski, A.; Zucchini, G.; Howell, S.J. Breast cancer: Current and future endocrine therapies. Mol. Cell. Endocrinol. 2013, 382, 695-723. [CrossRef] [PubMed]
83. Toy, W.; Shen, Y.; Won, H.; Green, B.; Sakr, R.A.; Will, M.; Li, Z.; Gala, K.; Fanning, S.; King, T.A.; et al. Esr1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 2013, 45, 1439-1445. [CrossRef] [PubMed]
84. Robinson, D.R.; Wu, Y.M.; Vats, P.; Su, F.; Lonigro, R.J.; Cao, X.; Kalyana-Sundaram, S.; Wang, R.; Ning, Y.; Hodges, L.; et al. Activating esr1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 2013, 45, 1446-1451. [CrossRef] [PubMed]
85. Jeselsohn, R.; Yelensky, R.; Buchwalter, G.; Frampton, G.; Meric-Bernstam, F.; Gonzalez-Angulo, A.M.; Ferrer-Lozano, J.; Perez-Fidalgo, J.A.; Cristofanilli, M.; Gomez, H.; et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res. 2014, 20, 1757-1767. [CrossRef] [PubMed]
86. Merenbakh-Lamin, K.; Ben-Baruch, N.; Yeheskel, A.; Dvir, A.; Soussan-Gutman, L.; Jeselsohn, R.; Yelensky, R.; Brown, M.; Miller, V.A.; Sarid, D.; et al. D538g mutation in estrogen receptor-alpha: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013, 73, 6856-6864. [CrossRef] [PubMed]
87. Liedtke, C.; Mazouni, C.; Hess, K.R.; Andre, F.; Tordai, A.; Mejia, J.A.; Symmans, W.F.; Gonzalez-Angulo, A.M.; Hennessy, B.; Green, M.; et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26, 1275-1281. [CrossRef] [PubMed]
88. Balko, J.M.; Giltnane, J.M.; Wang, K.; Schwarz, L.J.; Young, C.D.; Cook, R.S.; Owens, P.; Sanders, M.E.; Kuba, M.G.; Sanchez, V.; et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014, 4, 232-245. [CrossRef] [PubMed]
89. De Mattos-Arruda, L.; Cortes, J.; Santarpia, L.; Vivancos, A.; Tabernero, J.; Reis-Filho, J.S.; Seoane, J. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat. Rev. Clin. Oncol. 2013, 10, 377-389. [CrossRef] [PubMed]
90. Dawson, S.J.; Tsui, D.W.; Murtaza, M.; Biggs, H.; Rueda, O.M.; Chin, S.F.; Dunning, M.J.; Gale, D.; Forshew, T.; Mahler-Araujo, B.; et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013, 368, 1199-1209. [CrossRef] [PubMed]
91. Olsson, E.; Winter, C.; George, A.; Chen, Y.; Howlin, J.; Tang, M.H.; Dahlgren, M.; Schulz, R.; Grabau, D.; vanWesten, D.; et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol. Med. 2015, 7, 1034-1047. [CrossRef] [PubMed]
92. Klevebring, D.; Lindberg, J.; Rockberg, J.; Hilliges, C.; Hall, P.; Sandberg, M.; Czene, K. Exome sequencing of contralateral breast cancer identifies metastatic disease. Breast Cancer Res. Treat. 2015, 151, 319-324. [CrossRef] [PubMed]
93. Alkner, S.; Tang, M.H.; Brueffer, C.; Dahlgren, M.; Chen, Y.; Olsson, E.; Winter, C.; Baker, S.; Ehinger, A.; Ryden, L.; et al. Contralateral breast cancer can represent a metastatic spread of the first primary tumor: Determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing. Breast Cancer Res. 2015, 17, 102. [CrossRef] [PubMed]
94. Bennett, N.C.; Farah, C.S. Next-generation sequencing in clinical oncology: Next steps towards clinical validation. Cancers (Basel) 2014, 6, 2296-2312. [CrossRef] [PubMed]